Position of Dietitians of Canada and the American Dietetic Association: Nutrition intervention in the care of persons with human immunodeficiency virus infection

Canadian Journal of Dietetic Practice and Research

Volumn 61, Issue 2, 2000, Pages 77-87

  Fields Gardner, Cade ^a   Ayoob, Keith Thomas ^b  

^a Cutting Edge   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0345807537     PISSN: 14863847     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (133)

1. United Nations AIDS Project and the World Health Organization Web site at http://www.unaids.org. Accessed April 12, 2000. AIDS epidemic update. 1998; December 1-17.
2. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report. 1999;11(1):1-42. Available at http://www.cdc.gov/nchstp/hiv_aids/stats/hasrlink.htm. Accessed April 12, 2000.
3. Division of HIV/AIDS Surveillance, Bureau of HIV/AIDS, STD and TB. Laboratory Centre for Disease Control. HIV and AIDS in Canada: Surveillance Report to December 31, 1998. April, 1999. Health Canada, Ontario, Canada. http://www.hc-sc.gc.ca/hpb/lcdc/publicat.html. Accessed April 12, 2000.
4. Shapiro MF, Morton SC, McCaffrey DF, Senterfitt JW, Fleishman JA, Perlman JF, et al. Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. JAMA 1999;281(24):2305-2315.
5. Oleske JM, Rothpletz-Puglia PM, Winter H. Historical perspectives on the evolution in understanding the importance of nutritional care in pediatric HIV infection. J Nutr 1996;126(10 Suppl):2663S-2673S.
6. Kuhn L, Thomas PA, Singh T, Tsai WY. Long-term survival of children with human immunodeficiency virus infection in New York City: estimates from population-based surveillance data.Am J Epidemiol 1998;147(9):846-854.
7. Rivera S, Briggs W, Qian D, Sattler FR. Levels of HIV RNA are quantitatively related to prior weight loss in HIV-associated wasting. J Acquir Immune Defic Syndr Hum Retrovirol 1998;17(5):411-418.
8. Semba RD, Tang AM. Micronutrients and the pathogenesis of human immunodeficiency virus infection. Br J Nutr 1999;81(3):181-189.
9. Henderson RA, Saavedra JM. Nutritional considerations and management of the child with human immunodeficiency virus infection. Nutrition 1995;11(2):121-128.
10. Sharpstone D, Murray C, Ross H, Phelan M, Crane R, Lepri AC, et al. The influence of nutritional and metabolic status on progression from asymptomatic HIV infection to AIDS-defining diagnosis. AIDS 1999;13(10):1221-1226.
11. Kotler DP, Tierney AR, Wang J, Pierson RN Jr. Magnitude of body-cell-mass depletion and the timing of death from wasting in AIDS. Am J Clin Nutr 1989;50(3):444-447.
12. Moore RD, Chaisson RE. Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS 1999;13(14):1933-1942.
13. Strawford A, Hellerstein M. The etiology of wasting in the human immunodeficiency virus and acquired immunodeficiency syndrome. Semin Oncol 1998;25(2 suppl 6):76-81.
14. Grinspoon S, Corcoran C, Miller K, Biller BM, Askari H, Wang E, et al. Body composition and endocrine function in women with acquired immunodeficiency syndrome wasting. J Clin Endocrinol Metab 1997;82(5):1332-7.
15. Mulligan K, Tai VW, Schambelan M. Cross-sectional and longitudinal evaluation of body composition in men with HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 1997;15(1):43-38.
16. nd ed. Norwalk, CT: Appleton & Lange; 1991:507-557.
17. Ott M, Lembcke B, Fischer H, Jager R, Polat H, Geier H, et al. Early changes of body composition in human immunodeficiency virus-infected patients: tetrapolar body impedance analysis indicates significant malnutrition. Am J Clin Nutr 1993;57:15-19.
18. Kertzner RM, Goetz R, Todak G, Cooper T, Lin SH, Reddy MM, et al. Cortisol levels, immune status, and mood in homosexual men with and without HIV infection. Am J Psychiat 1993;150(11):1674-1678.
19. Rivera S, Briggs W, Qian D, Sattler FR. Levels of HIV RNA are quantitatively related to prior weight loss in HIV-associated wasting. J Acquir Immune Defic Syndr Hum Retrovirol 1998;17(5):411-418.
20. Baum MK, Shor-Posner G, Lu Y, Rosner B, Sauberlich HE, Fletcher MA, et al. Micronutrients and HIV disease progression. AIDS 1995;9(9):1051-1056.
21. Skurnick JH, Bogden JD, Baker H, Kemp FW, Sheffett A, Quatrrone G, Louria DB. Micronutrient profiles in HIV-1 infected heterosexual adults. J Acquir Immune Def Syndr Hum Retrovirol 1996;12(1):75-83.
22. Savarino A, Pescarmona GP, Boelaert JR. Iron metabolism and HIV infection: reciprocal interactions with potentially harmful consequences? Cell Biochem Funct 1999;17(4):279-287.
23. Patrick L. Nutrients and HIV: part one - beta carotene and selenium. Altern Med Rev 1999;4(6):403-413.
24. Lacey CJ, Murphy ME, Sanderson MJ, Monteiro EF, Vail A, Schorah CJ. Antioxidant micronutrients and HIV infection. Int J STD AIDS 1996;7(7):485-489.
25. nd Ed. East Norwalk, CT: Appleton & Lange;1991:507-511.
26. Allard JP, Aghdassi E, Chau J, Salit I, Walmsley S. Oxidative stress and plasma antioxidant micronutrients in humans with HIV infection. Am J Clin Nutr 1998;67(1):143-147.
27. Kotler DP. Wasting syndrome: nutrition support in HIV infection. Acquir Immune Defic Syndr Res Hum Retrovirol 1994;10(8):931-934.
28. Melchior JC. Metabolic aspects of HIV: associated wasting. Biomed Pharmacother 1997;51(10):455-460.
29. Kotler DP. Human immunodeficiency virus-related wasting: malabsorption syndromes. Semin Oncol 1998;25(2 suppl 6):70-75.
30. Jimenez-Exposito MJ, Garcia-Lorda P, Alonso-Villaverde C, de Virgala CM, Sola R, Masana L, et al. Effect of malabsorption on nutritional status and resting energy expenditure in HIV-infected patients. AIDS 1998;12(15):1965-1972.
31. Koch J, Garcia-Shelton YL, Neal EA, Chan MF, Weaver KE, Cello JP. Steatorrhea: a common manifestation in patients with HIV/AIDS. Nutrition 1996;12(7-8):507-510.
32. Tepper RE, Simon D, Brandt LJ, Nutrovits R, Lee MJ. Intestinal permeability in patients infected with the human immunodeficiency virus. Am J Gastrenterol 1994;89(6):878-882.
33. Pernet P, Vittecoq D, Kodjo A, Randrianarisolo MH, Dumitrescu L, Blondon H, et al. Intestinal absorption and permeability in human immunodeficiency virus-infected patients. Scand J Gastrenterol 1999;34(1):29-34.
34. Sharpstone D, Neild P, Crane R, Taylor C, Hodgson C, Sherwood R, et al. Small intestinal transit, absorption, and permeability in patients with AIDS with and without diarrhea. Gut 1999;45(1):70-76.
35. Coodley GO, Loveless MO, Nelson HD, Coodley MK. Endocrine function in the HIV wasting syndrome. J Acquire Immune Defic Syndr 1994;7(1):46-51.
36. Hirschfeld S. Dysregulation of growth and development in HIV-infected children. J Nutr 1996;126(10 Suppl):2614S-2650S.
37. Carr A, Samaras K, Thorisdottir A, Kaufman GR, Chisholm DJ, Dooper DA. Diagnosis, prediction, and natural course of HIV-1 protease inhibitor-associated lipodystophy, hyperlipidaemia, and diabetes mellitus. A cohort study. Lancet 1999;353(9170):2093-2099.
38. Smith K, Germain M, Decker C, Yeager J, Skelton H. Increased soft tissue in the posterior cervical and upper back area of patients on HIV-1 protease inhibitors. J Cutan Med Surg 1999;3(4):211-217.
39. Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS 1999;13(18):2493-2505.
40. Kotler DP, Rosenbaum K, Wang J, Pierson RN. Studies of body composition and fat distribution in HIV-infected and control subjects. J Acquir Immune Defic Syndr 1999;20(3):228-237.
41. Mulligan K, Grunfeld C, Tai VW, Algren H, Pang M, Chernoff DN, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 1000;23(1):35-43.
42. Fields-Gardner C, Thomson CA, Rhodes SS. A Clinician's Guide to Nutrition in HIV and AIDS. Chicago, American Dietetic Association, 1997.
43. American Dietetic Association. Cost-effectiveness of medical nutrition therapy. J Am Diet Assoc 1995;95(1):88-91.
44. McMahon K, Decker G, Ottery FD. Integrating proactive nutritional assessment in clinical practices to prevent complications and cost. Semin Oncol 1998;25(2 Suppl 6):20-27.
45. American Dietetic Association. Identifying patients at risk: The American Dietetic Association's definitions for nutrition screening and nutrition assessment. K Am Diet Assoc 1994;94(8):838-839.
46. Winston JA, Burns GC, Klotman PE. The human immunodeficiency virus (HIV) epidemic and HIV-associated nephropathy. Semin Nephrol 1998;18(4):373-377.
47. Dube M, Johnson D, Currier J, Leedom J. Protease inhibitor-associated hypertriglyceridemia. Lancet 1997;350:713-714.
48. Dassopoulos T, Ehrenpreis ED. Acute pancreatitis in human immunodeficiency virus-infected patients: a review. Am J Med 1999;107(1):78-84.
49. Behrens G, Dejam A, Schmidt H, Balks HJ, Brabant G, Korner T, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999;13(10):F63-F70.
50. Yarasheski KE, Tebas P, Sigmund C, Dagogo-Jack S, Bohrer A, Turk J, et al. Insulin resistance in HIV protease inhibitor-associated diabetes. J Acquir Immune Defic Syndr 1999;21(3):209-216.
51. Vigouroux C, Gharakhanian S, Salhi Y, Nguyen TH, Chevenne D, Capeau J, Rozenbaum W. Diabetes, insulin resistance and dyslipidaemia and lipodystrophic HIV-infected patients on highly active antiretroviral therapy. Diabetes Metab 1999;25(3):225-232.
52. Hadigan C, Miller K, Corcoran C, Anderson E, Basgoz N, Grinspoon S. Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women. J Clin Endocrinol Metab 1999;84(6):1932-1937.
53. Walli R, Herfort O, Michl GM, Demant T, Jager H, Dieterle C, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998;12(15):F167-F173.
54. Kotler DP, Rosenbaum K, Wang J, Pierson RN. Studies of body composition and fat distribution in HIV-infected and control subjects. J Acquired Immimodefic Syndr 1999;20:228-237.
55. Engelson EE, Kotler DP, Tan YX, Wang J, Pierson RN, Heymsfield SB. Altered fat and skeletal muscle distribution in HIV-infected patients reporting increased abdominal girth. Am J Clin Nutr 1999;69:1162-1169.
56. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999;353(9170):2093-2099.
57. Yanovski JA, Miller KD, Kino T, Friedman TC, Chrousos GP, Tsigos C, Falloon J. Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy. J Clin Endocrinol Metab 1999;84(6):1925-1931.
58. Renard E, Fabre J, Paris F, Reynes J, Bringer J. Syndrome of body fat redistribution in HIV-1-infected patients: relationships to cortisol and catecholamines. Clin Endocrinol 1999;51(2):223-230.
59. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystophy. Lancet 1999;354(9184):1112-1115.
60. Saint-Marc T, Partisani M, Poizot-Martin I, Bruno F, Rouviere O, Lang JM. et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999;13(13):1659-1667.
61. Carbonnel F, Maslo C, Beaugerie L, Carrat F, Wirbel E, Aussel C. Effect of indinavir on HIV-related wasting. AIDS 1998;12(14):1777-1784.
62. Silva M, Skolnik PR, Gorbach SL, Spiegelman D, Wilson IB, Fernandez-DiFranco MG, Knox TA. The effect of protease inhibitors on weight and body composition in HIV-infected patients. AIDS 1998;12(13):1645-1651.
63. Nutrition Screening Initiative. Nutrition Interventions Manual for Professionals Caring for Older Americans: Executive Summary. Washington, DC: Nutrition Screening Initiative; 1992.
64. Fenton M, Silverman E, Vazzo L HIV/AIDS adult medical nutrition therapy protocol. In: Gilbreath J, Inman-Felton A, Johnson EQ, Robinson G, Smith K, eds Medical Nutrition Therapy Across the Continuum of Care. Chicago, The American Dietetic Association; 1998.
65. Heller L, Rothpletz-Puglia P, Morris V, Papthakis P. HIV/AIDS children/adolescents medical nutrition therapy protocol. In: Gilbreath J, Inman-Felton A, Johnson EQ, Robinson G, Smith K, eds Medical Nutrition Therapy Across the Continuum of Care. Chicago, The American Dietetic Association and Morris Health Care; 1998.
66. National Cholesterol Education Program. Available at http://www.nhlbi.nih.gov.
67. Vogel RA. The management of hypercholesterolemia in patients with coronary artery disease: guidelines for primary care. Clin Cornerstone 1998;1(1):51-64.
68. American Diabetes Association: clinical practice recommendations 1997. Diabetes Care 1997;20(suppl 1):S1-S70.
69. American Diabetes Association. Nutrition recommendations and principles for people with diabetes mellitus. Diabetes Care -1000;23(suppl). Available online at http://journal.diabetes.org/FullText/ Supplements/DiabetesCare/Supplement100/s43.htm
70. Saavedra JM, Henderson RA, Perman JA, Huton N, Livingston RA, Yolken RH. Longitudinal assessment of children born to mothers with human immunodeficiency virus infection. Archives of Adolescent Medicine 1995;149:497-502.
71. McKinney RE Jr, Robertson JW. Effect of human immunodeficiency virus infection on the growth of young children. Duke Pediatric AIDS Clinical Trials Unit. J Pediatr 1993;123:579-582.
72. Weight, height, and human immunodeficiency virus infection in young children of infected mothers. The European Collaborative Study. Pediatr Infect Dis J 1995;14:685-690.
73. Zuckerman GB, Sanchez JL, Conway EE. Neurologic complications of HIV infections in children. Pediatr Ann 1998;27(10):635-639.
74. Mintz M. Neurological and developmental problems in pediatriC HIV infection. J Nutr 1996;126(10 Suppl):2663S-267S.
75. LePage P, Msellati P, Hitimana DG, Bazubagira A, VanGoethem C, Simonon A, et al, Growth of human immunodeficiency type 1-infected and uninfected children: a prospective cohort study in Kigali, Rwanda 1988 to 1993. Pediatr Inf Dis J 1996;15(6)479-485.
76. Peters VB, Rosh JR, Mugrditchian L, Birnbaum AH, Benkov KJ, Hodes DS, LeLeiko NS. Growth failure is the first expression of malnutrition in children with human immunodeficiency virus infection. Mt Sinai J Med 1998;65(1):1-4.
77. Pollack H, Glasberg H, Lee E, Nirenberg A, David R, Krasinski D, et al. Impaired early growth of infants perinatally infected with human immunodeficiency virus: Correlation with viral load. J Pediatr 1997;130:915-922.
78. Miller TL, Awnetwant EL, Evans S, Morris VM, Vazquez IM, McIntosh K. Gastrostomy tube supplementation for HIV-infected children. Pediatrics 1995;96(4):696-702.
79. Henderson RA, Saavedra JM, Perman JA, Hutton N, Livingston RA, Yolken RH. Effect of enterai tube feeding on growth of children with symptomatic human immunodeficiency virus infection. J Pediatr Gastroneterol Nutr 1994;18(4):429-434.
80. Winter H. Gastrointestinal tract function and malnutrition in HIV-infected children. J Nutr 1996;126(10 Suppl):2620S-2622S.
81. Hirschfeld S. Dysregulation of growth and development in HIV-infected children. J Nutr 1996;126(10 Suppl):2614S-2650S.
82. Arpadi SM, Horlick MN, Wang J, Cugg P, Bamji M, Kotler DP. Body composition in prepubertal children with human immunodeficiency virus type 1 infection. Arch Pediatr Adolesc Med 1998;152(7):688-693.
83. Heller L, Fox S, Hell KJ, Church JA. Development of an instrument to assess nutritional risk factors for children infected with human immunodeficiency virus. J Am Diet Assoc 2000; 100:323-329.
84. Rabenck L, Palmer A, Knowles JB, Seidehamel RJ, Harris CL, Merkal KL, et al. A randomized controlled trial evaluating nutrition counseling with or without oral supplementation in malnourished HIV-infected patients. J Am Diet Assoc 1998;98(4):434-438.
85. Gagnon AJ, Therrien R, Editors. HIV Medication Guide. V2.05. 1999. Available at: www.jag.ca/on/hiv. Accessed September 2, 1999.
86. Centers for Disease Control and Prevention. Food and water-borne bacterial diseases. Revised March 9, 1995. Available at: www.cdc.gov/ ncidod/diseases/bacter/foodborn.htm. Accessed September 2, 1999.
87. Black RF. Transmission of HIV-1 in the breastfeeding process. J Am Diet Assoc 1996;96:267-274.
88. st Edition. Pottstown, PA: Food-Medication Interactions, Inc.; 1998.
89. th Edition. Hyde Park, VT: Antimicrobial Therapy, Inc.; 1999.
90. Position of The American Dietetic Association: medical nutrition therapy and pharmacotherapy. J Am Diet Assoc 1999;99(2):227-230.
91. Shephard RJ. Exercise, immune function and HIV infection. J Sports Med Phys Fitness 1998;38(2):101-110.
92. Evans WJ, Roubenoff R, Shevitz A. Exercise and the treatment of wasting: aging and human immunodeficiency virus infection. Semin Oncol 1998;25(2 Suppl 6):112-122.
93. Wagner G, Rabkin J, Rabkin R. Exercise as a mediator of psychological and nutritional effects of testosterone therapy in HIV+ men. Med Sci Sports Exerc 1998;30(6):811-817.
94. Haslett P, Hempstead M, Seidman C, Diakun J, Vasquez D, Freedman VH, Kaplan G. The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus. AIDS Res Hum Retroviruses 1997;13(12):1047-1054.
95. Mulligan K, Bloch AS. Energy expenditure and protein metabolism in human immunodeficiency virus infection and cancer cachexia. Semin Oncol 1998;25(2 suppl 6):82-91.
96. Position of The American Dietetic Association: Vitamin and mineral supplementation. J Am Diet Assoc 1996;96(1):73-77.
97. Tang AM, Graham NM, Saah AJ. Effects of micronutrient intake on survival in human immunodeficiency virus type 1 infection. Am J Epidemiol 1996;143(12):1244-1256.
98. Allard JP, Aghdassi E, Chau J, Tam C, Kovacs CM, Salit IE, Walmsley SL. Effects of vitamin E and C supplementation on oxidative stress and viral load in HIV-infected subjects. AIDS 1998;12(13):1653-1659.
99. Position of The American Dietetic Association: Food and nutrition misinformation. J Am Diet Assoc 1995;95(6):705-707.
100. Calabrese C, Wenner CA, Reeves C, Turet P, Standish LJ. Treatment of human immunodeficiency virus-positive patients with complementary and alternative medicine: a survey of practitioners. J Altern Complement Med 1998;4(3):281-287.
101. MacIntyre RC, Holzerner WL, Philippek M. Complementary and alternative medicine in HIV/AIDS. Part I: Issues and context. J Assoc Nurses AIDS Care 1997;8(1):23-31.
102. MacIntyre RC, Holzerner WL Complementary and alternative medicine in HIV/AIDS. Part II: selected literature review. J Assoc Nurses AIDS Care 1997;8(2):25-38.
103. Grinspoon S, Corcoran C, Miller K, Wang E, Hubbard J, Schoenfeld D, et al. Determinants of increased energy expenditure in HIV-infected women. Am J Clin Nutr 1998;68(3):720-725.
104. Shevitz AH, Knox TA, Spiegelman D, Roubenoff R, Gorbach SL, Skolnik PR. Elevated resting energy expenditure among HIV-seropositive persons receiving highly active antiretroviral therapy. AIDS 1999;13(11):1351-1357.
105. Beau JP, Imboua-Coulibaly L. Dehydration: an important factor of mortality in human immunodeficiency virus (HIV) seropositive malnourished children. Bull Soc Path Exot 1997;90(2):71-73.
106. Baynes RD, Cook JD. Current issues in iron deficiency. Curr Opin Hemat 1996;3(2):145-149.
107. Kotler DP, Tierney AR, Culpepper-Morgan JA, Wang J, Pierson RN. Effect of home total parenteral nutrition on body composition in patients with acquired immunodeficiency syndrome. J Parenter Enteral Nutr 1990;14(5):454-458.
108. Henderson RA, Talusan K, Hutton N, Yolken RH, Caballero B. Whole body protein turnover in children with human immunodeficiency virus (HIV) infection. Nutrition 1999;15(3):189-194.
109. Hellerstein MK. De novo lipogenesis in humans: metabolic and regulatory aspects. Eur J Clin Nutr 1999;53(Suppl 1):S53-S65.
110. Hoh R, Pelfini A, Neese RA, Chan M, Cello JP, Cope FO, et al. De novo lipogenesis predicts short-term body composition response by bioelectrical impedance analysis to oral nutritional supplements in HIV-associated wasting. Am J Clin Nutr 1998;68(1):154-163.
111. Henderson RA, SaavedraJM, Perman JA, Hutton N, Livingston RA, Yolken RH. Effect of enteral tube feeding on growth of children with symptomatic human immunodeficiency virus infection. J Pediatr Gastroneterol Nutr 1994;18(4):429-434.
112. Kotler DP, Rosenbaum K, Wang J, Pierson RN. Studies of body composition and fat distribution in HIV infection and control subjects. J Acquir Immune Defic Syndr Hum Retrovirol 1999;20(3):228-237.
113. Strawford A, Hellerstein M. The etiology of wasting in the human immunodeficiency virus and acquired immunodeficiency syndrome. Semin Oncol 1998;25(2 Suppl 6):76-81.
114. Heller L. HIV-associated weight loss in pediatric patients. Clinician 1999;17(4):32-39.
115. Mulligan K, Tai VW, Schambelan M. Effects of chronic growth hormone treatment on energy intake and resting energy metabolism in patients with human immunodeficiency virus-associated wasting - a clinical research center study. J Clin Endocrinol Metab 1998;83(5):1542-1547.
116. Schambelan M, Mulligan K, Grunfeld C, Daar ES, LaMarca A, Kotler DP, Wang J, Bozette SA, Breitmeyer JB. Recombinant human growth hormone in patients with HIV-associated wasting. A randomized, placebo-controlled trial. Serostim Study Group. Ann Intern Med 1996;124(11):873-882.
117. Miller K, Corcoran C, Armstrong C, Caramelli K, Anderson E, Cotton D, et al. Transdermal testosterone administration in women with acquired immunodeficiency syndrome wasting: a pilot study. J Clin Endocrinol Metab 1998;83(8):2717-2715.
118. Grinspoon S, Corcoran C, Askari H, Scheonfeld D, Wolf L, Burrows B, et al. Effects of androgen administration in men with the AIDS wasting syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998;129(1):18-26.
119. Saint-Marc T, Touraine JL. Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy. AIDS 1999;13(8):1000-1002.
120. Gold J, Batterham M. Nandrolone decanoate; use in HIV-associated lipodystrophy syndrome: a pilot study, Int J STD AIDS 1999;10(8):558.
121. Wanke C, Gerrior J, Kantaros J, Coakley E, Albrecht M. Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV. AIDS 1999;13(15):2099-2103.
122. Roubenoff R, Weiss L, McDermott A, Heflin T, Coutier CJ, Wood M, Gorbach S. A pilot study of exercise training to reduce trunk fat in adults with HIV-associated fat redistribution. AIDS 1999;13(11):1373-1375.
123. Wanke C. Single-agent/combination therapy of human immunodeficiency virus-related wasting. Semin Oncol 1998;25(2 suppl 6):98-103.
124. Strawford A, Barbieri T, Van Loan M, Parks E, Catlin D, Barton N, Neese R, Christiansen M, King J, Hellerstein MK. Resistance exercise and supraphysiologic androgen therapy in eugonadal men with HIV-related weight loss: a randomized controlled trial. JAMA 1999;281(14):1282-1290.
125. Mocroft A, Kirk O, Barton SE, Dietrich M, Proenca R, Colebunders R, et al. Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA Study Group. AIDS 1999;13(8):943-950.
126. Echevarria KL, Hardin TC, Smith JA. Hyperlipidemia associated with protease inhibitor therapy. Ann Pharmacotber 1999;33(7-8):859-863.
127. Melroe NH, Kopaczewski J, Henry K, Huebsch. Intervention for hyperlipidemia associated with protease inhibitors. J Assoc Nurses AIDS Care 1999;10(4):55-69.
128. Meyer L, Rabaud C, Ziegler O, May T, Drouin P. Protease inhibitors, diabetes mellitus and blood lipids. Diabetes Metab 1998;24(6):547-549.
129. University of California, San Francisco. HIV InSite HIV Drug Database. Accessed April 12, 2000. Available at: www.anvdb.ucsf.edu.
130. AIDS Nutrition Services Alliance, 1400 I Street NW, Suite 1220, Washington, DC 20005; 202-289-5650;http://www.aidsnutrition.org. Accessed April 12, 2000.
131. Bellesky K. What is the Ryan White CARE Act? Positive Communication 1999;4(4):5-6.
132. Sarubin A. The Health Professional's Guide to Popular Dietary Supplements. Chicago, American Dietetic Association, 2000.
133. nd Edition. New York, Pharmaceutical Products Press, 1993.